Is Sermorelin Legal in Arizona?

The Short Answer on Arizona Legal Status

Sermorelin is not banned in Arizona. A physician-issued prescription combined with dispensing from a licensed compounding pharmacy is all that is legally required to obtain it in the state. The drug itself is not a controlled substance under federal law, and the Arizona Revised Statutes contain no specific prohibition on it.

The nuance is federal, not state. The FDA does not recognize sermorelin as a "bulk drug substance" on its Category 1 (permitted) list under the 2019 guidance framework for 503A pharmacies, which creates ongoing regulatory uncertainty for compounders. That uncertainty does not make sermorelin illegal for patients; it governs which pharmacies can legally compound it and under what conditions.

Federal Compounding Law: Where the Real Complexity Lives

The 503A vs. 503B Distinction

Two pathways govern compounded sermorelin in the United States. Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) covers traditional compounding pharmacies that fill individual patient prescriptions. Section 503B covers outsourcing facilities that may produce larger batches without patient-specific prescriptions. FDA guidance on compounding explains both frameworks in detail.

Under 503A, a pharmacy may compound a drug that is not on FDA's "do not compound" list, provided it is compounded from a bulk substance that either appears on the permitted bulk list or has been nominated for review. Sermorelin's regulatory position here is the source of ongoing discussion among compounders, because it has not received a formal Category 1 approval on the 503A bulk list.

Under 503B, outsourcing facilities may compound drugs that appear on FDA's drug shortage list or that are copies of commercially available drugs meeting specific criteria. Sermorelin is not on the current shortage list, which limits routine 503B production.

What "Not on the Permitted List" Actually Means for Patients

The fact that sermorelin lacks an explicit Category 1 designation does not mean the FDA has prohibited it. The agency has not placed sermorelin on its "Category 2" (do-not-compound) list either. This gray area means some 503A pharmacies continue to compound it while awaiting final agency determination, accepting the regulatory risk at the pharmacy level rather than passing legal liability to patients or prescribers.

Patients in Arizona who receive sermorelin from a pharmacy operating within these rules are not violating any federal or state law. The FDA's current bulk substances list should be verified at time of prescribing, as the agency updates it periodically.

Historical Approved Product Context

Sermorelin acetate was previously approved by the FDA as Geref (Serono) for the diagnosis of growth-hormone deficiency in children and for treatment of idiopathic growth-hormone deficiency in children. The product was voluntarily withdrawn from the US market in 2002 for business reasons, not safety concerns. A 2005 NIH-indexed case series documented its clinical use in adults, helping establish the evidence base that compounding physicians rely on today.

Arizona State Law and the Pharmacy Board

Arizona Revised Statutes: No Sermorelin-Specific Prohibition

Searching Arizona Revised Statutes Title 32 (Professions and Occupations) and Title 36 (Public Health and Safety) turns up no statute that specifically restricts sermorelin. The Arizona Medical Practice Act (A.R.S. §32-1401 et seq.) governs physician conduct but does not enumerate specific drugs as off-limits outside of controlled substances under A.R.S. §36-2501 et seq. Sermorelin does not appear on Arizona's Schedule I, IV controlled-substance lists.

The Arizona Board of Pharmacy (AZBOP) requires compounding pharmacies operating in-state to hold a valid compounding permit and comply with USP Chapter 797 sterile compounding standards for any injectable product. USP Chapter 797 standards set the baseline for sterility testing, beyond-use dating, and cleanroom requirements that any pharmacy dispensing injectable sermorelin must meet.

Out-of-State Pharmacies Shipping to Arizona

Many patients in Arizona obtain sermorelin from out-of-state 503A compounding pharmacies. These pharmacies must hold an Arizona non-resident pharmacy permit from AZBOP to ship prescriptions into the state. A patient receiving shipments from a pharmacy that does not hold this permit may unknowingly be receiving product from an unlicensed source. Verifying pharmacy licensure on the AZBOP license verification portal is a practical step before filling any prescription.

Prescribing Authority in Arizona

Licensed physicians (MD, DO), nurse practitioners with full prescriptive authority, and physician assistants with a prescribing license may all write prescriptions for compounded sermorelin in Arizona. Arizona is a full-practice-authority state for nurse practitioners, meaning NPs do not require physician supervision to prescribe. That regulatory environment makes telehealth access to sermorelin relatively straightforward compared to more restrictive states.

The FDA's Evolving Peptide Policy and What It Means Going Forward

The 2023 and 2024 Bulk Substance Nominations

The FDA has accepted nominations for sermorelin review under the 503A bulk substance process, meaning the agency is actively evaluating it rather than simply ignoring it. Stakeholder comments submitted during open comment periods have argued for Category 1 status based on the drug's historical approval, documented safety profile, and medical need. The outcome of that review will determine whether 503A pharmacies have clear legal footing to continue compounding it.

Until a final determination is published in the Federal Register, the status remains technically unsettled at the federal compounding-pharmacy level. The FDA's compounding policy page provides the most current list status.

How Physician Liability Is Framed

The American Academy of Anti-Aging Medicine and other professional groups have published position statements supporting GHRH analogue use in adults with documented growth-hormone deficiency. Prescribers operating within the standard of care, conducting appropriate lab evaluation (IGF-1, GH stimulation testing), and documenting medical necessity are on firmer ground than those prescribing without workup. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults notes that "biochemical confirmation of GHD is required before initiation of GH therapy," a standard that applies equally to secretagogues like sermorelin used in lieu of recombinant GH.

The table below summarizes how to think about the layered legal framework before prescribing or obtaining sermorelin in Arizona.

| Layer | Governing Body | Sermorelin Status | |---|---|---| | Federal drug scheduling | DEA | Not scheduled; not a controlled substance | | Federal compounding (503A) | FDA | Under review; not on Category 1 or Category 2 list | | Federal compounding (503B) | FDA | Not on shortage list; limited batch production pathway | | Arizona statute | AZ Legislature | No prohibition found in ARS Title 32 or 36 | | Arizona pharmacy permit | AZBOP | Compounding permit and USP 797 compliance required | | Prescribing authority | AZ Medical Board / BON | MD, DO, NP (full practice), PA with prescribing license |

Clinical Profile of Sermorelin: Why Physicians Prescribe It

Mechanism of Action

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth-hormone-releasing hormone (GHRH 1-29). Binding to GHRH receptors on somatotroph cells in the anterior pituitary, it stimulates pulsatile secretion of endogenous growth hormone (GH). Because it works through the body's own feedback axis, GH levels remain subject to somatostatin suppression, reducing the risk of sustained supraphysiologic GH elevation that can occur with exogenous recombinant GH injection.

Evidence Base

A randomized, double-blind, placebo-controlled trial by Vittone et al. Published in Metabolism (1997, N=89) found that sermorelin acetate administered for 6 months produced a statistically significant increase in IGF-1 levels and lean body mass compared to placebo in older adults (P<0.05). That study is frequently cited in compounding-pharmacy formulary justifications submitted to the FDA.

A 2004 paper by Walker et al. In the Journal of Clinical Endocrinology and Metabolism (N=96) confirmed that pulsatile GHRH administration restored GH secretory dynamics in adults with growth-hormone deficiency, with IGF-1 normalization in 71% of treated subjects at 12 weeks. PubMed entry for Walker 2004.

The Endocrine Society's 2019 clinical practice guideline states directly: "We recommend GH therapy for adults with GHD who have symptoms and signs that impair quality of life, and in whom the diagnosis has been confirmed biochemically." Sermorelin is used as an alternative to recombinant GH when a physician determines that stimulating endogenous production is preferable to exogenous replacement.

Common Prescribing Indications in Practice

Physicians prescribing sermorelin in Arizona most often do so for:

• Documented adult growth-hormone deficiency with low IGF-1 (<116 ng/mL in adults aged 30-60 per laboratory reference ranges)
• Age-related decline in GH secretion causing fatigue, reduced lean mass, and impaired recovery
• Adjunct support during testosterone replacement therapy (TRT) to maintain GH axis function
• Off-label use in body composition optimization under direct physician supervision

Off-label prescribing is legal in the United States and in Arizona. The FDA regulates drug manufacturers, not the practice of medicine. Physicians may prescribe approved or compounded drugs for uses not listed on a product label, provided they can document a rational clinical basis.

How to Get Sermorelin in Arizona

Step 1: Establish Medical Necessity with Lab Work

Before any legitimate provider writes a sermorelin prescription, they will order baseline labs. The minimum reasonable workup includes serum IGF-1 (insulin-like growth factor 1), a comprehensive metabolic panel, fasting glucose, and HbA1c. Some physicians also order a GH stimulation test (glucagon or arginine/GHRH stimulation) for formal GHD confirmation per Endocrine Society criteria.

Bringing current lab results to a telehealth consultation shortens the evaluation process considerably.

Step 2: Consult a Licensed Arizona Provider or Telehealth Platform

Arizona law permits telehealth prescribing after a valid patient-provider relationship is established, which in practice means a synchronous video or phone consultation during which the provider takes a medical history, reviews labs, and documents clinical reasoning. The provider must be licensed in Arizona or hold an Arizona telehealth certificate.

Hormone-focused telehealth platforms operating in Arizona are required to maintain the same prescribing standards as in-person clinics. A provider who offers to prescribe sermorelin without reviewing labs or taking a history is operating below the standard of care regardless of platform.

Step 3: Verify Pharmacy Licensure

Once a prescription is issued, confirm the dispensing pharmacy holds an active Arizona compounding permit (for in-state pharmacies) or an Arizona non-resident pharmacy permit (for out-of-state shippers). Ask the pharmacy directly which compounding standards they follow and whether their sterile products are tested for potency, sterility, and endotoxins per USP 797. A reputable pharmacy will provide a certificate of analysis (COA) for each batch.

Step 4: Injection Training and Follow-Up

Injectable sermorelin requires proper subcutaneous injection technique. Reputable prescribers provide injection training (video or written) at the time of dispensing. Follow-up IGF-1 testing at 8-12 weeks confirms the drug is producing the expected biochemical response. A target IGF-1 in the upper-normal range for age and sex is typically the clinical endpoint.

Risks, Contraindications, and Safety Signals

Sermorelin is generally well tolerated. The most commonly reported adverse effects in clinical trials include injection-site reactions (redness, swelling), transient flushing, and headache. The FDA prescribing information for the previously approved Geref formulation lists these as the primary adverse events at therapeutic doses.

Contraindications include active malignancy (GH axis stimulation is theoretically contraindicated in patients with known or suspected cancer), hypersensitivity to GHRH analogues, and pregnancy. Patients with diabetes should monitor glucose levels, as GH elevation can reduce insulin sensitivity. A fasting glucose and HbA1c above thresholds (>100 mg/dL fasting or HbA1c >5.7%) warrant extra caution and closer monitoring per standard endocrinology practice.

Sermorelin does not suppress the hypothalamic-pituitary axis the way exogenous GH does. Because it works through pulsatile feedback-regulated secretion, the risk of acromegaly from therapeutic doses is considered low, though no long-term randomized trial beyond 12 months in adults is available in the published literature.

Frequently Asked Questions